Innovative tumour targeting therapeutics in Cushing's disease.
Best Pract Res Clin Endocrinol Metab
; 36(6): 101701, 2022 12.
Article
in En
| MEDLINE
| ID: mdl-36511278
ABSTRACT
Cushing's disease (CD) is the most frequent form of endogenous hypercortisolism. Management of this devastating condition relies on pituitary surgery, while effective pharmacological treatment mainly focus on periphery targeting pharmaceuticals. Approved tumour-targeting drugs are limited to dopamine agonists and somatostatin analogues with frequently low efficacy and substantial side effects. Discoveries on the genetics and pathophysiology of corticotroph tumorigenesis brought forward new potential pharmacological targets. Compounds such as retinoic acid although promising in preclinical studies, are not as efficient in the clinic. Others, such as, silibinin, gefitinib and roscovitine are effective in preclinical models, but their efficacy and safety still needs to be determined in patients with CD.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Adenoma
/
Pituitary ACTH Hypersecretion
/
ACTH-Secreting Pituitary Adenoma
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Best Pract Res Clin Endocrinol Metab
Journal subject:
ENDOCRINOLOGIA
/
METABOLISMO
Year:
2022
Document type:
Article
Affiliation country:
Germany